Items Tagged with 'Pfizer'

ARTICLES

Purchase ceiling raised for two stock picks.

Updates for May 2013: Purchase Price Raised for Pfizer and J&J

In light of significant recent developments, The Turnaround Letter is raising its maximum buy price for these large cap purchase recommendations.
Read More
PFE Complete $11.85 billion Sale

Pfizer Completes Sale of Nutrition Business to Nestlé

On November 30, Pfizer Inc. (NYSE: PFE) announced that it has completed the sale of its Nutrition business to Nestlé for $11.85 billion in cash, following the conclusion of the required regulatory process in most markets.


Read More
PFE Announces Revenues of $14.0 billion

Pfizer Reports Third-Quarter 2012 Results

On November 1, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for third-quarter 2012. Third-quarter 2012 revenues were $14.0 billion, a decrease of 16% compared with $16.6 billion in the year-ago quarter, which reflects an operational decline of $1.9 billion, or 12%, and the unfavorable impact of foreign exchange of $699 million, or 4%.


Read More
PFE Reports Second Quarter 2012 Revenues of $15.1 Billion

Pfizer Second Quarter Financials Released

On July 31, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2012.


Read More
PFE Obtains FDA Approval for Lyrica

Pfizer FDA Approval Received

On June 21, 2012, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved the use of Lyrica® (pregabalin) capsules CV for the management of neuropathic pain associated with spinal cord injury.


Read More
PFE Reports 7% Revenue Decrease

Pfizer Financials Announced

On May 1, 2012, Pfizer Inc. (NYSE: PFE) reported financial results for first-quarter 2012.


Read More
PFE to Divest Nutrition Business

Pfizer and Nestle Nutrition Business Agreement Announced

On April 23, 2012, Pfizer Inc. (NYSE: PFE) announced that it has entered into an agreement to divest its Nutrition business to Nestle for $11.85 billion in cash.


Read More
Pfizer Buys Vitamin C Icon

Pfizer Acquisition Announced

On February 27, 2012, Pfizer Inc. (NYSE:PFE) announced the acquisition of privately-held Alacer Corp....


Read More

Pfizer Recall Announced

On February 1, 2012, Pfizer Inc. (NYSE: PFE) announced that it has voluntarily recalled 14 lots of Lo/Ovral®-28 (norgestrel and ethinyl estradiol)Tablets and 14 lots of Norgestrel and Ethinyl Estradiol Tablets (generic) for customers in the U.S. market.


Read More

Pfizer FDA Approval Received

On January 27, 2012, Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) has approved INLYTA® (axitinib), a kinase inhibitor, for the treatment of patients with advanced renal cell carcinoma (RCC) after failure of one prior systemic therapy.


Read More

Profit from The Turnaround Letter's...

  • Market-Beating Investment Results
  • 27+ Years of Turnaround Experience
  • Diverse Stock Picks for Today's Unpredictable Market

Distressed Investing Blog

Distressed Investing Blog

Buy & Hold: The Turnaround Letter's Time-Tested Investing Strategy

Since publishing our first issue back in 1986, we’ve always recommended investors exercise patience. "Beware an Itchy Trigger Finger" identified ten stock picks with particularly promising long-term potential--and they all had the added bonus of paying dividends over 3% to further reward investor patience. Given our contrarian slant, each of these stocks was also generally out of favor with mainstream investors at the time of recommendation--adding value stock appeal. Read More.

Free Stock Report

 

Put George Putnam's 27+ years of market-beating, contrarian investing advice to work for you, and give your portfolio a boost with this FREE stock report.

Current Total Returns

 

Value Stock Profit

Total returns cover the fulll year 2013.

Note: Returns are not adjusted for inflation.

 

Read More.

Sample Issue

TL Spotlight

 

Value Stock Picks

 

MoneyShow.com named George's stock pick top performer for all of 2013 and shared this feature interview to update investors on MTG's status and highlight select year-end bounce candidates.

 

Learn more.